Transabdominal Intestinal Ultrasound (IUS) in Crohn’s Disease

Clinical Bottom Line

IBD Assessment Tool	Primary Advantage	Limitation
Standard Colonoscopy	Allows direct mucosal biopsy and visual confirmation of early ulcers.	Requires brutal laxative prep, deep sedation, and cannot measure the true transmural thickness of the bowel wall.
Intestinal Ultrasound (IUS)	Point-of-care, zero prep, zero sedation; actively measures full-thickness bowel wall edema in real-time.	Highly operator dependent; difficult to visualize the deep rectum or in severely obese patients.

The Zero-Prep Biomarker

Relying on endoscopic scopes to repeatedly measure the efficacy of a new biologic therapy is incredibly burdensome for the patient. Repeated colonoscopies every 6 months to check if a Crohn's ulcer has healed inevitably leads to profound patient burnout and high rates of non-compliance. In 2026, Point-of-Care Intestinal Ultrasound (IUS) has rapidly emerged as a highly specific, bedside alternative in advanced IBD centers.

Measuring Transmural Thickness

Crohn's Disease is inherently a transmural pathology—it inflames all structural layers of the bowel, not just the superficial surface. Using a standard, high-frequency linear ultrasound probe placed externally on the abdomen, a trained gastroenterologist can instantly visualize the inflamed terminal ileum. A normal terminal ileum wall should measure < 3mm thick. If the IUS immediately flags a hyperemic, hypervascular bowel wall measuring 7mm, the physician definitively knows the biologic therapy has failed, entirely bypassing the need to subject the patient to a full colonoscopic prep to confirm the obvious ongoing inflammation.

Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: 2026. This article is intended for physicians.

For your teaching file

Save this article as a PDF

Drop your email and we'll open a print-ready version you can save as a PDF — and you'll start getting our weekly GI endoscopy newsletter.

← All articles